4JONES R, I,YDEARD S. Irritable bowel syndrome in the general population. BMJ, 1992,304 (6819) :87 - 89.
5TALLEY N J, ZINSMEISTER AR, VAN DYKE C, et al. Epidemiolohy of colonic symptoms and the irritable bowel syndrome. Gastroenterology, 1991 ,101 (4) :927 -934.
6TAN YM, GOM KL, MUHIDAYAtt R, et al. Prevalence of irritable bowel syndrome in young adult Malaysians: A survey amonh medical students. J Gastroenterol Hepatol, 2005,18 (12) : 1412 - 1416.
3El-Salhy M, Seim I,Chopin L, et al. Irritable bowel syndrome : therole of gut neuroendocrine peptides [ J]. Front Biosci ( Elite Ed),2012, 4: 2783-2800.
4Grundmann 0,Yoon SL. Irritable bowel syndrome: epidemiology, di-agnosis and treatment: an update for health-care practitioners [J]. JGastroenterol Hepatol, 2010,25(4) : 691-699.
5Sperber AD, Shvartzman P, Friger M, et al. A comparative reap-praisal of the Rome H and Rome 瓜 diagnostic criteria : are we gettingcloser to the ‘ true * prevalence of irritable bowel syndrome. [ J]. EurJ Gastroenterol Hepatol, 2007,19(6) : 441 -447.
6Zung WW. A self-rating depression scale [J]. Arch Gen Psychiatry,1965, 12: 63-70.
7Cremonini F, Talley NJ. Irritable bowel syndrome ; epidemiology,natural history,health care seeking and emerging risk factors [ J ].Gastroenterol Clin North Am, 2005,34(2) : 189-204.
8Al-Judaibi B, Chande N, Gregor J. Safety and efficacy of tegaserodtherapy in patients with irritable bowel syndrome or chronic constipa-tion [J]. Can J Clin Pharmacol, 2010 , 17(1) : el94-e200.
9Lovell RM,Ford AC. Global prevalence of and risk factors for irrita-ble bowel syndrome : a meta-analysis [ J ]. Clin Gastroenterol Hepa-tol, 2012, 10(7) : 712-721, e4.
10Kang JY. Systematic review : the influence of geography and ethnicityin irritable bowel syndrome [J]. Aliment Pharmacol Ther, 2005 , 21(6): 663-676.
